PALO ALTO, Calif., Feb. 18, 2021 /PRNewswire/ -- Varian (NYSE:
VAR) announced it has joined the Cancer Drug Development Forum
(CDDF) as an industry partner. This makes Varian the first medical
technology company to join CDDF, the leading non-competitive drug
development platform in Europe.
CDDF's objective is to stimulate advancement in cancer drug
development and access.
CDDF's integrative approach brings together leading voices from
academia, the pharmaceutical industry, regulatory authorities,
health technology assessors, policymakers, and patient groups to
improve cancer treatment. Varian is joining the CDDF Industry
Partners Platform to support and expand its mission by combining
the advancement of drugs with the power of radiotherapy or physical
therapies, as well as improving access to combination
therapies.
"Fostering multidisciplinary cancer care has long been a key
priority for Varian," said Ricky
Sharma, MD, PhD, vice president of clinical affairs at
Varian. "Our CDDF membership will accelerate progress towards our
joint goal to discover the most effective combinations of new
cancer drugs with advanced radiotherapy and physical therapies. It
takes all of us working as one to make big leaps in conquering
cancer with multimodality treatment."
The CDDF Industry Partners Platform is composed of large and
small partners from the pharmaceutical industry who work together
in a neutral space to discuss innovative drug development in
oncology. The inclusion of Varian broadens the non-profit
organization's scope to encompass collaboration with a medical
technology company.
"CDDF has an integrative approach and we are excited to welcome
Varian to our community of industry partners," said Professor
Jaap Verweij, CDDF Managing
Director. "We will continue to promote multi-stakeholder
collaboration, now with Varian's unique contribution, to advance
oncology therapeutics."
About Varian
At Varian, we envision a world without
fear of cancer. For more than 70 years, we have developed, built
and delivered innovative cancer care technologies and solutions for
our clinical partners around the globe to help them treat millions
of patients each year. With an Intelligent Cancer Care approach, we
are harnessing advanced technologies like artificial intelligence,
machine learning and data analytics to enhance cancer treatment and
expand access to care. Our 10,000 employees across 70 locations
keep the patient and our clinical partners at the center of our
thinking as we power new victories in cancer care. Because,
for cancer patients everywhere, their fight is our fight. For more
information, visit http://www.varian.com and follow
@VarianMedSys on Twitter.
About CDDF
The Cancer Drug Development Forum (CDDF)
is a leading non-competitive drug development platform in
Europe whose sole objective is to
stimulate advancement in cancer drug development and access.
CDDF integrative approach aims to bring together leading voices
from academia, the pharmaceutical industry, regulatory authorities,
health technology assessors, policymakers, and patient groups to
accelerate effective drug development in oncology treatment and
shorten time to market, and time to patient access.
For more information on Cancer Drug Development Forum, please
visit www.cddf.org
Press Contact
Aimee
Corso
Health + Commerce
+1 (310) 780-2661
aimee@healthandcommerce.com
Investor Relations Contact
Anshul Maheshwari
Vice President, Investor Relations
+1 (650) 424-5631
investors@varian.com
View original
content:http://www.prnewswire.com/news-releases/varian-becomes-first-medical-technology-company-joining-the-cancer-drug-development-forum-301230758.html
SOURCE Varian